NDLI: Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide

Content Provider	PubMed Central
Author	Stocchi, Fabrizio Torti, Margherita
Copyright Year	2016
Abstract	Safinamide (SAF) is a new drug developed for the treatment of Parkinson’s disease (PD). It is a benzylamino derivative with multiple mechanisms of action and antiparkinsonian, anticonvulsant, and neuroprotective properties. SAF inhibits monoamine oxidase B and dopamine reuptake and glutamate release, blocks voltage-dependent sodium channels, and modulates calcium channels. Although the antiparkinsonian effect can be ascribed in part to the inhibition of the monoamine oxidase B, which is complete at 50 mg, the enhanced benefit seen at the 100 mg dose is probably due to nondopaminergic mechanisms. SAF will represent an important option for patients with both early and advanced PD. In early PD patients, the addition of SAF to dopamine agonists may be an effective treatment strategy to improve motor function, prolong the use of dopamine agonists, and/or delay the introduction of levodopa. In advanced parkinsonian patients, SAF has been demonstrated to significantly increase on time with no, or nontroublesome dyskinesias. All studies performed have demonstrated its efficacy in benefiting both short-term and long-term quality-of-life outcomes in both early and advanced PD patients. SAF has been investigated in long-term (24 months), double-blind, placebo-controlled studies, where it showed a very good safety profile. SAF has not been studied in de novo PD patients, and its potential positive effect on dyskinesia deserves further dedicated studies.
Related Links	http://dx.doi.org/10.2147/dddt.s77749
Ending Page	618
Page Count	10
Starting Page	609
File Format	PDF
ISSN	11778881
e-ISSN	11778881
Journal	Drug Design, Development and Therapy
Volume Number	10
Language	English
Publisher	Dove Medical Press
Publisher Date	2016-02-01
Access Restriction	Open
Rights Holder	Dove Medical Press
Subject Keyword	Pharmacology Drug Discovery Pharmaceutical Science Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Drug Discovery Pharmacology Pharmaceutical Science

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Advances with microRNAs in Parkinson’s disease research

Emerging strategies and therapies for treatment of Paget’s disease of bone

Neuroprotective therapies for glaucoma

Current and novel drug therapies for idiopathic pulmonary fibrosis

Available and emerging treatments for Parkinson’s disease: a review

Glycyrrhetinic acid and E.resveratroloside act as potential plant derived compounds against dopamine receptor D3 for Parkinson’s disease: a pharmacoinformatics study

Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies

Changes in surface expression of N-methyl-D-aspartate receptors in the striatum in a rat model of Parkinson’s disease

Advances with microRNAs in Parkinson’s disease research

Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide

Similar Documents

Advances with microRNAs in Parkinson’s disease research

Emerging strategies and therapies for treatment of Paget’s disease of bone

Neuroprotective therapies for glaucoma

Current and novel drug therapies for idiopathic pulmonary fibrosis

Available and emerging treatments for Parkinson’s disease: a review

Glycyrrhetinic acid and E.resveratroloside act as potential plant derived compounds against dopamine receptor D3 for Parkinson’s disease: a pharmacoinformatics study

Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies

Changes in surface expression of N-methyl-D-aspartate receptors in the striatum in a rat model of Parkinson’s disease

Advances with microRNAs in Parkinson’s disease research

Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide